# NEET PG, INI-CET & FMGE Clinical Medicine: PSM (Park), Pharmacology, Pathology & High-Yield Triads

> Preventive and Social Medicine (Park): National Health Mission, Universal Immunization Programme, epidemiology and biostatistics, biomedical waste color coding, pathology hallmarks, and pharmacology antidotes and teratogens.

- **Canonical URL:** https://flashcards.world/flashcards/sets/ec6156c2-af77-4a7a-a0c5-8857f5b019ec/
- **Markdown URL:** https://flashcards.world/flashcards/sets/ec6156c2-af77-4a7a-a0c5-8857f5b019ec.md
- **Category:** UPSC Civil Services (IAS/IPS), SSC CGL, CLAT Law & NEET PG / INI-CET India
- **Level:** advanced
- **Languages:** en → en
- **Total Cards:** 32

## Flashcards (32 Cards)

| # | Front (Term / Prompt) | Back (Definition / Answer) | Example | Multiple-Choice Options |
| :--- | :--- | :--- | :--- | :--- |
| 1 | What are the population norms in Plain versus Hilly/Tribal areas for a Sub-Centre, Primary Health Centre (PHC), and Community Health Centre (CHC) in India? | Sub-Centre (Ayushman Arogya Mandir): 5,000 in plains and 3,000 in hilly/tribal areas. Primary Health Centre (PHC, 4–6 beds, 1st Medical Officer contact): 30,000 in plains and 20,000 in hilly/tribal areas. Community Health Centre (CHC / First Referral Unit, 30 beds, 4 specialists): 1,20,000 in plains and 80,000 in hilly/tribal areas. | High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors. | A) Sub-Centre (Ayushman Arogya Mandir): 5,000 in plains and 3,000 in hilly/tribal areas. Primary Health Centre (PHC, 4–6 beds, 1st Medical Officer contact): 30,000 in plains and 20,000 in hilly/tribal areas. Community Health Centre (CHC / First Referral Unit, 30 beds, 4 specialists): 1,20,000 in plains and 80,000 in hilly/tribal areas. ✓; B) Sensitivity [TP/(TP+FN), rules OUT disease when negative — SnNout] and Specificity [TN/(TN+FP), rules IN disease when positive — SpPin] are intrinsic test properties and DO NOT change with prevalence.; C) The 4 mortality-reducing pillars of HFrEF (LVEF ≤40%) are: 1.; D) SLE: ANA (screening), Anti-dsDNA (nephritis/activity) & Anti-Smith (specific); Anti-histone in Drug-Induced Lupus. |
| 2 | Match the major toxicities of first-line Anti-Tubercular Drugs (INH, Rifampicin, Pyrazinamide, Ethambutol, Streptomycin) with their mechanisms. | Isoniazid (inhibits mycolic acid via katG): peripheral neuropathy (Vit B6 prevents), hepatotoxicity, drug-induced lupus. Rifampicin (inhibits rpoB RNA polymerase): orange secretions, potent CYP450 inducer. Pyrazinamide: hyperuricemia & hepatotoxicity. Ethambutol (inhibits embB): optic neuritis (red-green blindness). Streptomycin: CN VIII toxicity. | High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors. | A) The 4 mortality-reducing pillars of HFrEF (LVEF ≤40%) are: 1.; B) Minimal Change Disease (most common in children): normal LM, negative IF, podocyte foot process effacement on EM; selective albuminuria; steroid-responsive.; C) Acute Bacterial: turbid fluid, Neutrophils (>1000/µL), ↑↑ Protein (>100 mg/dL), ↓↓ Glucose (<40 mg/dL).; D) Isoniazid (inhibits mycolic acid via katG): peripheral neuropathy (Vit B6 prevents), hepatotoxicity, drug-induced lupus. Rifampicin (inhibits rpoB RNA polymerase): orange secretions, potent CYP450 inducer. Pyrazinamide: hyperuricemia & hepatotoxicity. Ethambutol (inhibits embB): optic neuritis (red-green blindness). Streptomycin: CN VIII toxicity. ✓ |
| 3 | Compare the Nephrotic Syndrome prototypes: Minimal Change Disease, Focal Segmental Glomerulosclerosis (FSGS), and Membranous Nephropathy. | Minimal Change Disease (most common in children): normal LM, negative IF, podocyte foot process effacement on EM; selective albuminuria; steroid-responsive. FSGS (HIV, heroin, sickle cell): segmental sclerosis on LM, steroid-resistant. Membranous Nephropathy (anti-PLA2R, HBV, solid tumors, SLE V): subepithelial deposits ('spike and dome'). | High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors. | A) Most cardiac murmurs increase with increased preload (Inspiration for right-sided murmurs — Carvallo's sign; Squatting).; B) Minimal Change Disease (most common in children): normal LM, negative IF, podocyte foot process effacement on EM; selective albuminuria; steroid-responsive. FSGS (HIV, heroin, sickle cell): segmental sclerosis on LM, steroid-resistant. Membranous Nephropathy (anti-PLA2R, HBV, solid tumors, SLE V): subepithelial deposits ('spike and dome'). ✓; C) Open Vial Policy APPLIES to liquid multi-dose vials (usable up to 28 days at +2°C to +8°C if VVM is active): OPV, DPT, Td, Hepatitis B, Pentavalent, liquid IPV, and PCV.; D) In Zero-Order kinetics, a constant AMOUNT of drug is eliminated per unit time because enzymes are saturated, so half-life (t₁/₂) increases with dose: 1. |
| 4 | Under the National Tuberculosis Elimination Programme (NTEP), what is the regimen for Drug-Sensitive TB and the BPaLM regimen for MDR/RR-TB? | NTEP uses upfront NAAT (CBNAAT/TrueNat detecting M. tuberculosis & rpoB Rifampicin resistance). Drug-Sensitive TB: 2 months Intensive Phase (HRZE daily) + 4 months Continuation Phase (HRE daily). For MDR/RR-TB, India adopted the 6-month all-oral BPaLM regimen: Bedaquiline + Pretomanid + Linezolid + Moxifloxacin. Nikshay Poshan gives ₹1,000/month. | High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors. | A) NTEP uses upfront NAAT (CBNAAT/TrueNat detecting M. tuberculosis & rpoB Rifampicin resistance). Drug-Sensitive TB: 2 months Intensive Phase (HRZE daily) + 4 months Continuation Phase (HRE daily). For MDR/RR-TB, India adopted the 6-month all-oral BPaLM regimen: Bedaquiline + Pretomanid + Linezolid + Moxifloxacin. Nikshay Poshan gives ₹1,000/month. ✓; B) In Zero-Order kinetics, a constant AMOUNT of drug is eliminated per unit time because enzymes are saturated, so half-life (t₁/₂) increases with dose: 1.; C) PSGN: 1–3 wks post-strep pharyngitis or 3–6 wks post-impetigo; cola-coloured hematuria, ↓ C3, subepithelial 'humps' on EM, granular IgG/C3 on IF.; D) Start aggressive IV 0.9% Normal Saline FIRST before IV regular insulin (0.1 U/kg/hr). |
| 5 | State the four colour-coded categories under India's Biomedical Waste Management Rules, 2016 (amended 2018) and their contents. | YELLOW (incineration): anatomical waste, blood-soiled dressings/plaster casts, expired medicines, microbiology cultures. RED (autoclaving + recycling): contaminated recyclable plastics/rubber—IV tubes, catheters, urine bags, vacutainers, syringes WITHOUT needles, gloves. WHITE (puncture-proof): metallic sharps/needles. BLUE: glassware & implants. | High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors. | A) YELLOW (incineration): anatomical waste, blood-soiled dressings/plaster casts, expired medicines, microbiology cultures. RED (autoclaving + recycling): contaminated recyclable plastics/rubber—IV tubes, catheters, urine bags, vacutainers, syringes WITHOUT needles, gloves. WHITE (puncture-proof): metallic sharps/needles. BLUE: glassware & implants. ✓; B) Isoniazid (inhibits mycolic acid via katG): peripheral neuropathy (Vit B6 prevents), hepatotoxicity, drug-induced lupus.; C) Type I (Immediate): IgE cross-linking on mast cells (anaphylaxis, asthma).; D) Most cardiac murmurs increase with increased preload (Inspiration for right-sided murmurs — Carvallo's sign; Squatting). |
| 6 | Identify the pathognomonic Histopathological Hallmarks and Inclusion Bodies frequently tested in NEET PG / INI-CET Pathology. | Aschoff bodies & Anitschkow myocytes: Rheumatic heart disease; Reed-Sternberg (CD15+ CD30+) cells: Classic Hodgkin lymphoma; Birbeck granules (CD1a+, Langerin+): Langerhans histiocytosis; Call-Exner bodies: Granulosa cell tumor; Schiller-Duval bodies (AFP+): Yolk sac tumor; Psammoma bodies: Papillary thyroid & Meningioma; Negri bodies: Rabies. | High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors. | A) SLE: ANA (screening), Anti-dsDNA (nephritis/activity) & Anti-Smith (specific); Anti-histone in Drug-Induced Lupus.; B) Acute Bacterial: turbid fluid, Neutrophils (>1000/µL), ↑↑ Protein (>100 mg/dL), ↓↓ Glucose (<40 mg/dL).; C) P. vivax: Chloroquine for 3 days (25 mg/kg total) + Primaquine 0.25 mg/kg daily for 14 days (eradicates hypnozoites; avoid in pregnancy, infants <1 yr, and G6PD deficiency). P. falciparum:…; D) Aschoff bodies & Anitschkow myocytes: Rheumatic heart disease; Reed-Sternberg (CD15+ CD30+) cells: Classic Hodgkin lymphoma; Birbeck granules (CD1a+, Langerin+): Langerhans histiocytosis; Call-Exner bodies: Granulosa cell tumor; Schiller-Duval bodies (AFP+): Yolk sac tumor; Psammoma bodies: Papillary thyroid & Meningioma; Negri bodies: Rabies. ✓ |
| 7 | Distinguish between Coagulative, Liquefactive, Caseous, Fat, and Fibrinoid Necrosis with their classic organ examples. | Coagulative: cell outlines preserved with ghost cells; hypoxic ischemia of all solid organs EXCEPT brain. Liquefactive: enzymatic digestion into fluid/pus; CNS infarcts and bacterial abscesses. Caseous: cheese-like necrosis with Langhans giant cells in TB. Fat: chalky calcium soaps in acute pancreatitis. Fibrinoid: immune complexes in PAN. | High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors. | A) PSGN: 1–3 wks post-strep pharyngitis or 3–6 wks post-impetigo; cola-coloured hematuria, ↓ C3, subepithelial 'humps' on EM, granular IgG/C3 on IF.; B) Coagulative: cell outlines preserved with ghost cells; hypoxic ischemia of all solid organs EXCEPT brain. Liquefactive: enzymatic digestion into fluid/pus; CNS infarcts and bacterial abscesses. Caseous: cheese-like necrosis with Langhans giant cells in TB. Fat: chalky calcium soaps in acute pancreatitis. Fibrinoid: immune complexes in PAN. ✓; C) Under Light's Criteria, a pleural effusion is EXUDATIVE if AT LEAST ONE is met: 1.; D) Series Testing (Test B done only if Test A is positive; positive only if BOTH A and B are positive): DECREASES net Sensitivity and NPV, but INCREASES net Specificity and PPV. |
| 8 | What is the treatment of Uncomplicated Plasmodium vivax versus Plasmodium falciparum malaria in India under NVBDCP guidelines? | P. vivax: Chloroquine for 3 days (25 mg/kg total) + Primaquine 0.25 mg/kg daily for 14 days (eradicates hypnozoites; avoid in pregnancy, infants <1 yr, and G6PD deficiency). P. falciparum: Artemether-Lumefantrine (ACT-AL) in NE India or Artesunate + Sulfadoxine-Pyrimethamine (ACT-SP) elsewhere for 3 days + single-dose Primaquine (0.75 mg/kg Day 2). | High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors. | A) SGLT2 Inhibitors (Empagliflozin, Dapagliflozin): block proximal SGLT2 causing glucosuria, weight loss, and HFrEF/CKD benefit, but risk Euglycemic DKA and Fournier gangrene.; B) Crohn's Disease: mouth to anus (terminal ileum, spares rectum), discontinuous 'skip lesions', TRANSMURAL inflammation, cobblestone mucosa, creeping fat, strictures ('string sign'), fistulas, non-caseating…; C) P. vivax: Chloroquine for 3 days (25 mg/kg total) + Primaquine 0.25 mg/kg daily for 14 days (eradicates hypnozoites; avoid in pregnancy, infants <1 yr, and G6PD deficiency). P. falciparum: Artemether-Lumefantrine (ACT-AL) in NE India or Artesunate + Sulfadoxine-Pyrimethamine (ACT-SP) elsewhere for 3 days + single-dose Primaquine (0.75 mg/kg Day 2). ✓; D) Sub-Centre (Ayushman Arogya Mandir): 5,000 in plains and 3,000 in hilly/tribal areas. |
| 9 | Compare the Nephritic Syndrome prototypes: Post-Streptococcal Glomerulonephritis (PSGN), IgA Nephropathy (Berger Disease), and Alport Syndrome. | PSGN: 1–3 wks post-strep pharyngitis or 3–6 wks post-impetigo; cola-coloured hematuria, ↓ C3, subepithelial 'humps' on EM, granular IgG/C3 on IF. IgA Nephropathy: synpharyngitic hematuria within 1–3 days of URI; normal C3; mesangial IgA. Alport Syndrome (X-linked COL4A5 Type IV collagen): nephritis + sensorineural deafness + anterior lenticonus. | High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors. | A) V1–V2: Septal (Proximal LAD); V3–V4: Anterior (LAD); V1–V6 + I, aVL: Extensive Anterior (Left Main/LAD); I, aVL, V5–V6: Lateral (Left Circumflex — LCx); II, III, aVF: Inferior (Right Coronary Artery —…; B) PSGN: 1–3 wks post-strep pharyngitis or 3–6 wks post-impetigo; cola-coloured hematuria, ↓ C3, subepithelial 'humps' on EM, granular IgG/C3 on IF. IgA Nephropathy: synpharyngitic hematuria within 1–3 days of URI; normal C3; mesangial IgA. Alport Syndrome (X-linked COL4A5 Type IV collagen): nephritis + sensorineural deafness + anterior lenticonus. ✓; C) Birth: BCG (ID, left arm, NS diluent), OPV-0, HepB.; D) Thalidomide: Phocomelia; Isotretinoin: craniofacial, thymic & cardiac defects; Valproate/Carbamazepine: Neural tube defects; Phenytoin: Fetal Hydantoin syndrome (cleft palate, nail hypoplasia); Lithium:… |
| 10 | Compare Case-Control and Cohort epidemiological study designs in terms of directionality, measure of association, and rare disease versus rare exposure suitability. | Case-Control Study: retrospective from Outcome to Exposure; fast, ideal for RARE DISEASES or long latency, calculates Odds Ratio (OR = ad/bc); prone to Recall & Selection Bias. Cohort Study: prospective from Exposure to Outcome; ideal for RARE EXPOSURES, directly measures Incidence, Relative Risk (RR = Ie/Iu), and Attributable Risk (AR = Ie - Iu). | High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors. | A) Case-Control Study: retrospective from Outcome to Exposure; fast, ideal for RARE DISEASES or long latency, calculates Odds Ratio (OR = ad/bc); prone to Recall & Selection Bias. Cohort Study: prospective from Exposure to Outcome; ideal for RARE EXPOSURES, directly measures Incidence, Relative Risk (RR = Ie/Iu), and Attributable Risk (AR = Ie - Iu). ✓; B) P. vivax: Chloroquine for 3 days (25 mg/kg total) + Primaquine 0.25 mg/kg daily for 14 days (eradicates hypnozoites; avoid in pregnancy, infants <1 yr, and G6PD deficiency). P. falciparum:…; C) t(9;22) BCR-ABL1: CML (Imatinib); t(8;14) c-MYC: Burkitt Lymphoma ('starry-sky'); t(14;18) BCL-2: Follicular Lymphoma; t(11;14) Cyclin D1: Mantle Cell Lymphoma; t(15;17) PML-RARA: Acute Promyelocytic…; D) Obstructive (FEV₁/FVC < 0.70): Asthma shows reversible obstruction (FEV₁ ↑ ≥12% and ≥200 mL post-bronchodilator) with normal/↑ DLCO; Emphysema has irreversible obstruction with ↓ DLCO (alveolar loss);… |
| 11 | What are the dynamic auscultation maneuvers that distinguish Hypertrophic Cardiomyopathy (HOCM) and Mitral Valve Prolapse (MVP) from Aortic Stenosis (AS)? | Most cardiac murmurs increase with increased preload (Inspiration for right-sided murmurs — Carvallo's sign; Squatting). The TWO exceptions are HOCM and MVP: maneuvers that DECREASE LV volume (Valsalva strain and Abrupt Standing) make the HOCM systolic murmur LOUDER and move the MVP click/murmur EARLIER; Squatting makes HOCM softer. | High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors. | A) Acute Bacterial: turbid fluid, Neutrophils (>1000/µL), ↑↑ Protein (>100 mg/dL), ↓↓ Glucose (<40 mg/dL).; B) NTEP uses upfront NAAT (CBNAAT/TrueNat detecting M.; C) t(9;22) BCR-ABL1: CML (Imatinib); t(8;14) c-MYC: Burkitt Lymphoma ('starry-sky'); t(14;18) BCL-2: Follicular Lymphoma; t(11;14) Cyclin D1: Mantle Cell Lymphoma; t(15;17) PML-RARA: Acute Promyelocytic…; D) Most cardiac murmurs increase with increased preload (Inspiration for right-sided murmurs — Carvallo's sign; Squatting). The TWO exceptions are HOCM and MVP: maneuvers that DECREASE LV volume (Valsalva strain and Abrupt Standing) make the HOCM systolic murmur LOUDER and move the MVP click/murmur EARLIER; Squatting makes HOCM softer. ✓ |
| 12 | How do you differentiate Crohn's Disease from Ulcerative Colitis across clinical, endoscopic, and histopathological features? | Crohn's Disease: mouth to anus (terminal ileum, spares rectum), discontinuous 'skip lesions', TRANSMURAL inflammation, cobblestone mucosa, creeping fat, strictures ('string sign'), fistulas, non-caseating granulomas, ASCA+. Ulcerative Colitis: starts in RECTUM and extends continuously in colon; MUCOSAL, crypt abscesses, 'lead-pipe' colon. | High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors. | A) Obstructive (FEV₁/FVC < 0.70): Asthma shows reversible obstruction (FEV₁ ↑ ≥12% and ≥200 mL post-bronchodilator) with normal/↑ DLCO; Emphysema has irreversible obstruction with ↓ DLCO (alveolar loss);…; B) Crohn's Disease: mouth to anus (terminal ileum, spares rectum), discontinuous 'skip lesions', TRANSMURAL inflammation, cobblestone mucosa, creeping fat, strictures ('string sign'), fistulas, non-caseating granulomas, ASCA+. Ulcerative Colitis: starts in RECTUM and extends continuously in colon; MUCOSAL, crypt abscesses, 'lead-pipe' colon. ✓; C) YELLOW (incineration): anatomical waste, blood-soiled dressings/plaster casts, expired medicines, microbiology cultures.; D) The 4 mortality-reducing pillars of HFrEF (LVEF ≤40%) are: 1. |
| 13 | Match the characteristic Oncogenes and Tumor Suppressor Genes with their associated human malignancies and chromosomal translocations. | t(9;22) BCR-ABL1: CML (Imatinib); t(8;14) c-MYC: Burkitt Lymphoma ('starry-sky'); t(14;18) BCL-2: Follicular Lymphoma; t(11;14) Cyclin D1: Mantle Cell Lymphoma; t(15;17) PML-RARA: Acute Promyelocytic Leukemia (Auer rods, DIC, treated with ATRA + Arsenic trioxide); RB1 (13q14): Retinoblastoma & Osteosarcoma; VHL (3p): Clear cell RCC; RET: MEN 2A/2B. | High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors. | A) t(9;22) BCR-ABL1: CML (Imatinib); t(8;14) c-MYC: Burkitt Lymphoma ('starry-sky'); t(14;18) BCL-2: Follicular Lymphoma; t(11;14) Cyclin D1: Mantle Cell Lymphoma; t(15;17) PML-RARA: Acute Promyelocytic Leukemia (Auer rods, DIC, treated with ATRA + Arsenic trioxide); RB1 (13q14): Retinoblastoma & Osteosarcoma; VHL (3p): Clear cell RCC; RET: MEN 2A/2B. ✓; B) Crohn's Disease: mouth to anus (terminal ileum, spares rectum), discontinuous 'skip lesions', TRANSMURAL inflammation, cobblestone mucosa, creeping fat, strictures ('string sign'), fistulas, non-caseating…; C) Start aggressive IV 0.9% Normal Saline FIRST before IV regular insulin (0.1 U/kg/hr).; D) Isoniazid (inhibits mycolic acid via katG): peripheral neuropathy (Vit B6 prevents), hepatotoxicity, drug-induced lupus. |
| 14 | Contrast the autoantibodies and clinical hallmarks of Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (Scleroderma), Sjögren Syndrome, and Dermatomyositis. | SLE: ANA (screening), Anti-dsDNA (nephritis/activity) & Anti-Smith (specific); Anti-histone in Drug-Induced Lupus. Limited Scleroderma (CREST): Anti-centromere (PAH risk). Diffuse Scleroderma: Anti-Scl-70 (ILD & renal crisis). Sjögren: Anti-Ro (SSA) & Anti-La (SSB). Dermatomyositis: Anti-Jo-1/Mi-2, Heliotrope rash, Gottron papules. | High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors. | A) SLE: ANA (screening), Anti-dsDNA (nephritis/activity) & Anti-Smith (specific); Anti-histone in Drug-Induced Lupus. Limited Scleroderma (CREST): Anti-centromere (PAH risk). Diffuse Scleroderma: Anti-Scl-70 (ILD & renal crisis). Sjögren: Anti-Ro (SSA) & Anti-La (SSB). Dermatomyositis: Anti-Jo-1/Mi-2, Heliotrope rash, Gottron papules. ✓; B) Under Light's Criteria, a pleural effusion is EXUDATIVE if AT LEAST ONE is met: 1.; C) Case-Control Study: retrospective from Outcome to Exposure; fast, ideal for RARE DISEASES or long latency, calculates Odds Ratio (OR = ad/bc); prone to Recall & Selection Bias.; D) SGLT2 Inhibitors (Empagliflozin, Dapagliflozin): block proximal SGLT2 causing glucosuria, weight loss, and HFrEF/CKD benefit, but risk Euglycemic DKA and Fournier gangrene. |
| 15 | Match the ECG leads to the corresponding myocardial wall and culprit coronary artery in ST-Elevation Myocardial Infarction (STEMI). | V1–V2: Septal (Proximal LAD); V3–V4: Anterior (LAD); V1–V6 + I, aVL: Extensive Anterior (Left Main/LAD); I, aVL, V5–V6: Lateral (Left Circumflex — LCx); II, III, aVF: Inferior (Right Coronary Artery — RCA; check V3R–V4R for RV infarct where nitrates are avoided); V1–V3 tall R waves with ST depression (V7–V9 ST elevation): Posterior MI (PDA). | High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors. | A) Start aggressive IV 0.9% Normal Saline FIRST before IV regular insulin (0.1 U/kg/hr).; B) Series Testing (Test B done only if Test A is positive; positive only if BOTH A and B are positive): DECREASES net Sensitivity and NPV, but INCREASES net Specificity and PPV.; C) Type I (Immediate): IgE cross-linking on mast cells (anaphylaxis, asthma).; D) V1–V2: Septal (Proximal LAD); V3–V4: Anterior (LAD); V1–V6 + I, aVL: Extensive Anterior (Left Main/LAD); I, aVL, V5–V6: Lateral (Left Circumflex — LCx); II, III, aVF: Inferior (Right Coronary Artery — RCA; check V3R–V4R for RV infarct where nitrates are avoided); V1–V3 tall R waves with ST depression (V7–V9 ST elevation): Posterior MI (PDA). ✓ |
| 16 | Which vaccines in India's Universal Immunization Programme follow the Open Vial Policy (usable up to 28 days) versus those discarded within 4 hours? | Open Vial Policy APPLIES to liquid multi-dose vials (usable up to 28 days at +2°C to +8°C if VVM is active): OPV, DPT, Td, Hepatitis B, Pentavalent, liquid IPV, and PCV. Open Vial Policy DOES NOT APPLY to lyophilized reconstituted vaccines: BCG, Measles/MR, and JE (must be discarded within 4 hours of reconstitution, as is Rotavirus). | High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors. | A) NTEP uses upfront NAAT (CBNAAT/TrueNat detecting M.; B) Coagulative: cell outlines preserved with ghost cells; hypoxic ischemia of all solid organs EXCEPT brain.; C) Open Vial Policy APPLIES to liquid multi-dose vials (usable up to 28 days at +2°C to +8°C if VVM is active): OPV, DPT, Td, Hepatitis B, Pentavalent, liquid IPV, and PCV. Open Vial Policy DOES NOT APPLY to lyophilized reconstituted vaccines: BCG, Measles/MR, and JE (must be discarded within 4 hours of reconstitution, as is Rotavirus). ✓; D) V1–V2: Septal (Proximal LAD); V3–V4: Anterior (LAD); V1–V6 + I, aVL: Extensive Anterior (Left Main/LAD); I, aVL, V5–V6: Lateral (Left Circumflex — LCx); II, III, aVF: Inferior (Right Coronary Artery —… |
| 17 | How do you interpret an Arterial Blood Gas (ABG) using the Anion Gap and Winter's Compensation Formula in Metabolic Acidosis? | In Metabolic Acidosis (pH <7.35, HCO₃⁻ <22 mEq/L), Serum Anion Gap = [Na⁺] - ([Cl⁻] + [HCO₃⁻]) (Normal = 8–12). High AG Acidosis (MUDPILES: Methanol, Uremia, DKA, Propylene glycol, INH/Iron, Lactic acidosis, Ethylene glycol, Salicylates). Normal AG Hyperchloremic Acidosis (Diarrhea, RTA). Winter's Formula: Expected PaCO₂ = (1.5 × HCO₃⁻) + 8 ± 2. | High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors. | A) Open Vial Policy APPLIES to liquid multi-dose vials (usable up to 28 days at +2°C to +8°C if VVM is active): OPV, DPT, Td, Hepatitis B, Pentavalent, liquid IPV, and PCV.; B) Paracetamol: N-acetylcysteine; Organophosphates: Atropine + Pralidoxime; Benzodiazepines: Flumazenil; Opioids: Naloxone; Beta-blockers: Glucagon; CCBs: IV Calcium + High-dose insulin; Methanol/Ethylene…; C) PSGN: 1–3 wks post-strep pharyngitis or 3–6 wks post-impetigo; cola-coloured hematuria, ↓ C3, subepithelial 'humps' on EM, granular IgG/C3 on IF.; D) In Metabolic Acidosis (pH <7.35, HCO₃⁻ <22 mEq/L), Serum Anion Gap = [Na⁺] - ([Cl⁻] + [HCO₃⁻]) (Normal = 8–12). High AG Acidosis (MUDPILES: Methanol, Uremia, DKA, Propylene glycol, INH/Iron, Lactic acidosis, Ethylene glycol, Salicylates). Normal AG Hyperchloremic Acidosis (Diarrhea, RTA). Winter's Formula: Expected PaCO₂ = (1.5 × HCO₃⁻) + 8 ± 2. ✓ |
| 18 | How does Light's Criteria differentiate a Transudative from an Exudative Pleural Effusion? | Under Light's Criteria, a pleural effusion is EXUDATIVE if AT LEAST ONE is met: 1. Pleural/Serum protein > 0.5; 2. Pleural/Serum LDH > 0.6; 3. Pleural LDH > 2/3 of upper normal serum LDH. Exudates occur in pneumonia/empyema (pH <7.20 needs chest tube), TB (ADA >40 U/L), and malignancy; Transudates occur in CHF, Cirrhosis, and Nephrotic syndrome. | High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors. | A) Birth: BCG (ID, left arm, NS diluent), OPV-0, HepB.; B) Under Light's Criteria, a pleural effusion is EXUDATIVE if AT LEAST ONE is met: 1. Pleural/Serum protein > 0.5; 2. Pleural/Serum LDH > 0.6; 3. Pleural LDH > 2/3 of upper normal serum LDH. Exudates occur in pneumonia/empyema (pH <7.20 needs chest tube), TB (ADA >40 U/L), and malignancy; Transudates occur in CHF, Cirrhosis, and Nephrotic syndrome. ✓; C) P. vivax: Chloroquine for 3 days (25 mg/kg total) + Primaquine 0.25 mg/kg daily for 14 days (eradicates hypnozoites; avoid in pregnancy, infants <1 yr, and G6PD deficiency). P. falciparum:…; D) Iron Deficiency: ↓ Iron, ↓ Ferritin (most specific), ↑ TIBC, ↑ RDW. |
| 19 | Differentiate the four Gell and Coombs Hypersensitivity Reactions (Types I, II, III, IV) with mechanisms and high-yield clinical examples. | Type I (Immediate): IgE cross-linking on mast cells (anaphylaxis, asthma). Type II (Cytotoxic/Antibody): IgG/IgM against cell/matrix antigens (AIHA, Goodpasture, Graves, Myasthenia, Pemphigus). Type III (Immune Complex): Ag-Ab complexes deposit in vessels (SLE, PSGN, Serum sickness). Type IV (Delayed): CD4+/CD8+ (Mantoux, contact dermatitis). | High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors. | A) Type I (Immediate): IgE cross-linking on mast cells (anaphylaxis, asthma). Type II (Cytotoxic/Antibody): IgG/IgM against cell/matrix antigens (AIHA, Goodpasture, Graves, Myasthenia, Pemphigus). Type III (Immune Complex): Ag-Ab complexes deposit in vessels (SLE, PSGN, Serum sickness). Type IV (Delayed): CD4+/CD8+ (Mantoux, contact dermatitis). ✓; B) Minimal Change Disease (most common in children): normal LM, negative IF, podocyte foot process effacement on EM; selective albuminuria; steroid-responsive.; C) In Metabolic Acidosis (pH <7.35, HCO₃⁻ <22 mEq/L), Serum Anion Gap = [Na⁺] - ([Cl⁻] + [HCO₃⁻]) (Normal = 8–12).; D) NTEP uses upfront NAAT (CBNAAT/TrueNat detecting M. |
| 20 | Which drugs follow Zero-Order (Capacity-Limited / Michaelis-Menten) Elimination Kinetics at therapeutic or toxic concentrations (Mnemonic: Zero WAFTT Power)? | In Zero-Order kinetics, a constant AMOUNT of drug is eliminated per unit time because enzymes are saturated, so half-life (t₁/₂) increases with dose: 1. Warfarin (high dose); 2. Alcohol (Ethanol); 3. Phenytoin (switches from first-order to zero-order in therapeutic range); 4. Theophylline; 5. Tolbutamide; 6. Salicylates (toxic doses). | High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors. | A) t(9;22) BCR-ABL1: CML (Imatinib); t(8;14) c-MYC: Burkitt Lymphoma ('starry-sky'); t(14;18) BCL-2: Follicular Lymphoma; t(11;14) Cyclin D1: Mantle Cell Lymphoma; t(15;17) PML-RARA: Acute Promyelocytic…; B) In Zero-Order kinetics, a constant AMOUNT of drug is eliminated per unit time because enzymes are saturated, so half-life (t₁/₂) increases with dose: 1. Warfarin (high dose); 2. Alcohol (Ethanol); 3. Phenytoin (switches from first-order to zero-order in therapeutic range); 4. Theophylline; 5. Tolbutamide; 6. Salicylates (toxic doses). ✓; C) V1–V2: Septal (Proximal LAD); V3–V4: Anterior (LAD); V1–V6 + I, aVL: Extensive Anterior (Left Main/LAD); I, aVL, V5–V6: Lateral (Left Circumflex — LCx); II, III, aVF: Inferior (Right Coronary Artery —…; D) YELLOW (incineration): anatomical waste, blood-soiled dressings/plaster casts, expired medicines, microbiology cultures. |
| 21 | How do Pulmonary Function Tests (Spirometry and DLCO) distinguish Asthma, Chronic Bronchitis, Emphysema, and Interstitial Lung Disease (ILD)? | Obstructive (FEV₁/FVC < 0.70): Asthma shows reversible obstruction (FEV₁ ↑ ≥12% and ≥200 mL post-bronchodilator) with normal/↑ DLCO; Emphysema has irreversible obstruction with ↓ DLCO (alveolar loss); Chronic Bronchitis has normal DLCO. Restrictive (FEV₁/FVC ≥ 0.70, ↓ TLC): ILD/Fibrosis has ↓ DLCO; chest-wall disease has normal DLCO. | High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors. | A) Obstructive (FEV₁/FVC < 0.70): Asthma shows reversible obstruction (FEV₁ ↑ ≥12% and ≥200 mL post-bronchodilator) with normal/↑ DLCO; Emphysema has irreversible obstruction with ↓ DLCO (alveolar loss); Chronic Bronchitis has normal DLCO. Restrictive (FEV₁/FVC ≥ 0.70, ↓ TLC): ILD/Fibrosis has ↓ DLCO; chest-wall disease has normal DLCO. ✓; B) Sub-Centre (Ayushman Arogya Mandir): 5,000 in plains and 3,000 in hilly/tribal areas.; C) Isoniazid (inhibits mycolic acid via katG): peripheral neuropathy (Vit B6 prevents), hepatotoxicity, drug-induced lupus.; D) Aschoff bodies & Anitschkow myocytes: Rheumatic heart disease; Reed-Sternberg (CD15+ CD30+) cells: Classic Hodgkin lymphoma; Birbeck granules (CD1a+, Langerin+): Langerhans histiocytosis; Call-Exner… |
| 22 | Match the high-yield Poisoning Antidotes tested in NEET PG and INI-CET Pharmacology. | Paracetamol: N-acetylcysteine; Organophosphates: Atropine + Pralidoxime; Benzodiazepines: Flumazenil; Opioids: Naloxone; Beta-blockers: Glucagon; CCBs: IV Calcium + High-dose insulin; Methanol/Ethylene glycol: Fomepizole; Iron: Deferoxamine; Lead: Succimer (DMSA); Cyanide: Hydroxocobalamin; Heparin: Protamine; Dabigatran: Idarucizumab. | High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors. | A) Coagulative: cell outlines preserved with ghost cells; hypoxic ischemia of all solid organs EXCEPT brain.; B) SLE: ANA (screening), Anti-dsDNA (nephritis/activity) & Anti-Smith (specific); Anti-histone in Drug-Induced Lupus.; C) Birth: BCG (ID, left arm, NS diluent), OPV-0, HepB.; D) Paracetamol: N-acetylcysteine; Organophosphates: Atropine + Pralidoxime; Benzodiazepines: Flumazenil; Opioids: Naloxone; Beta-blockers: Glucagon; CCBs: IV Calcium + High-dose insulin; Methanol/Ethylene glycol: Fomepizole; Iron: Deferoxamine; Lead: Succimer (DMSA); Cyanide: Hydroxocobalamin; Heparin: Protamine; Dabigatran: Idarucizumab. ✓ |
| 23 | List the high-yield Clinical Triads of Internal Medicine tested in NEET PG / INI-CET (Beck's, Virchow's, Charcot's, Whipple's, Cushing's, Hakim-Adams). | Beck's (Tamponade): hypotension, ↑ JVP, muffled heart sounds. Virchow's (DVT): endothelial injury, stasis, hypercoagulability. Charcot's (Cholangitis): fever, RUQ pain, jaundice (+ shock/confusion = Reynolds Pentad). Whipple's (Insulinoma): hypoglycemia <55 mg/dL, symptoms, glucose relief. Cushing's (↑ ICP): HTN, bradycardia, irregular breaths. | High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors. | A) In Metabolic Acidosis (pH <7.35, HCO₃⁻ <22 mEq/L), Serum Anion Gap = [Na⁺] - ([Cl⁻] + [HCO₃⁻]) (Normal = 8–12).; B) Sensitivity [TP/(TP+FN), rules OUT disease when negative — SnNout] and Specificity [TN/(TN+FP), rules IN disease when positive — SpPin] are intrinsic test properties and DO NOT change with prevalence.; C) Beck's (Tamponade): hypotension, ↑ JVP, muffled heart sounds. Virchow's (DVT): endothelial injury, stasis, hypercoagulability. Charcot's (Cholangitis): fever, RUQ pain, jaundice (+ shock/confusion = Reynolds Pentad). Whipple's (Insulinoma): hypoglycemia <55 mg/dL, symptoms, glucose relief. Cushing's (↑ ICP): HTN, bradycardia, irregular breaths. ✓; D) Coagulative: cell outlines preserved with ghost cells; hypoxic ischemia of all solid organs EXCEPT brain. |
| 24 | Compare the diagnostic performance in epidemiology when two screening tests are applied in Series versus in Parallel. | Series Testing (Test B done only if Test A is positive; positive only if BOTH A and B are positive): DECREASES net Sensitivity and NPV, but INCREASES net Specificity and PPV. Parallel Testing (both A and B done simultaneously; positive if EITHER A or B is positive): INCREASES net Sensitivity and NPV, but DECREASES net Specificity and PPV. | High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors. | A) Thalidomide: Phocomelia; Isotretinoin: craniofacial, thymic & cardiac defects; Valproate/Carbamazepine: Neural tube defects; Phenytoin: Fetal Hydantoin syndrome (cleft palate, nail hypoplasia); Lithium:…; B) Series Testing (Test B done only if Test A is positive; positive only if BOTH A and B are positive): DECREASES net Sensitivity and NPV, but INCREASES net Specificity and PPV. Parallel Testing (both A and B done simultaneously; positive if EITHER A or B is positive): INCREASES net Sensitivity and NPV, but DECREASES net Specificity and PPV. ✓; C) Iron Deficiency: ↓ Iron, ↓ Ferritin (most specific), ↑ TIBC, ↑ RDW.; D) In Metabolic Acidosis (pH <7.35, HCO₃⁻ <22 mEq/L), Serum Anion Gap = [Na⁺] - ([Cl⁻] + [HCO₃⁻]) (Normal = 8–12). |
| 25 | Compare the classic Cerebrospinal Fluid (CSF) profiles of Acute Bacterial, Viral (Aseptic), Tuberculous, and Cryptococcal Meningitis. | Acute Bacterial: turbid fluid, Neutrophils (>1000/µL), ↑↑ Protein (>100 mg/dL), ↓↓ Glucose (<40 mg/dL). Viral: Lymphocytic, normal/mildly ↑ Protein, NORMAL Glucose. Tuberculous: cobweb coagulum, Lymphocytic, ↑↑ Protein, ↓ Glucose. Cryptococcal (AIDS CD4 <100): high opening pressure, lymphocytic, positive India ink & Cryptococcal Antigen (CrAg). | High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors. | A) Acute Bacterial: turbid fluid, Neutrophils (>1000/µL), ↑↑ Protein (>100 mg/dL), ↓↓ Glucose (<40 mg/dL). Viral: Lymphocytic, normal/mildly ↑ Protein, NORMAL Glucose. Tuberculous: cobweb coagulum, Lymphocytic, ↑↑ Protein, ↓ Glucose. Cryptococcal (AIDS CD4 <100): high opening pressure, lymphocytic, positive India ink & Cryptococcal Antigen (CrAg). ✓; B) Case-Control Study: retrospective from Outcome to Exposure; fast, ideal for RARE DISEASES or long latency, calculates Odds Ratio (OR = ad/bc); prone to Recall & Selection Bias.; C) In Zero-Order kinetics, a constant AMOUNT of drug is eliminated per unit time because enzymes are saturated, so half-life (t₁/₂) increases with dose: 1.; D) Crohn's Disease: mouth to anus (terminal ileum, spares rectum), discontinuous 'skip lesions', TRANSMURAL inflammation, cobblestone mucosa, creeping fat, strictures ('string sign'), fistulas, non-caseating… |
| 26 | Compare the mechanisms and distinct adverse effects of SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors in Type 2 Diabetes Mellitus. | SGLT2 Inhibitors (Empagliflozin, Dapagliflozin): block proximal SGLT2 causing glucosuria, weight loss, and HFrEF/CKD benefit, but risk Euglycemic DKA and Fournier gangrene. GLP-1 Agonists (Semaglutide, Liraglutide): weight loss & ASCVD benefit; avoid in MEN2/Medullary Thyroid Cancer. DPP-4 Inhibitors (Linagliptin—safe in CKD): weight-neutral. | High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors. | A) Iron Deficiency: ↓ Iron, ↓ Ferritin (most specific), ↑ TIBC, ↑ RDW.; B) Obstructive (FEV₁/FVC < 0.70): Asthma shows reversible obstruction (FEV₁ ↑ ≥12% and ≥200 mL post-bronchodilator) with normal/↑ DLCO; Emphysema has irreversible obstruction with ↓ DLCO (alveolar loss);…; C) Sensitivity [TP/(TP+FN), rules OUT disease when negative — SnNout] and Specificity [TN/(TN+FP), rules IN disease when positive — SpPin] are intrinsic test properties and DO NOT change with prevalence.; D) SGLT2 Inhibitors (Empagliflozin, Dapagliflozin): block proximal SGLT2 causing glucosuria, weight loss, and HFrEF/CKD benefit, but risk Euglycemic DKA and Fournier gangrene. GLP-1 Agonists (Semaglutide, Liraglutide): weight loss & ASCVD benefit; avoid in MEN2/Medullary Thyroid Cancer. DPP-4 Inhibitors (Linagliptin—safe in CKD): weight-neutral. ✓ |
| 27 | Summarize the four Guideline-Directed Medical Therapy (GDMT) drug classes that reduce mortality in Heart Failure with Reduced Ejection Fraction (HFrEF). | The 4 mortality-reducing pillars of HFrEF (LVEF ≤40%) are: 1. ARNI (Sacubitril/Valsartan, or ACEi/ARB with a 36-hour washout before ARNI); 2. Evidence-based Beta-Blockers (Bisoprolol, Carvedilol, or Metoprolol succinate); 3. Mineralocorticoid Receptor Antagonists (Spironolactone/Eplerenone); and 4. SGLT2 Inhibitors (Dapagliflozin/Empagliflozin). | High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors. | A) The 4 mortality-reducing pillars of HFrEF (LVEF ≤40%) are: 1. ARNI (Sacubitril/Valsartan, or ACEi/ARB with a 36-hour washout before ARNI); 2. Evidence-based Beta-Blockers (Bisoprolol, Carvedilol, or Metoprolol succinate); 3. Mineralocorticoid Receptor Antagonists (Spironolactone/Eplerenone); and 4. SGLT2 Inhibitors (Dapagliflozin/Empagliflozin). ✓; B) Aschoff bodies & Anitschkow myocytes: Rheumatic heart disease; Reed-Sternberg (CD15+ CD30+) cells: Classic Hodgkin lymphoma; Birbeck granules (CD1a+, Langerin+): Langerhans histiocytosis; Call-Exner…; C) Most cardiac murmurs increase with increased preload (Inspiration for right-sided murmurs — Carvallo's sign; Squatting).; D) Case-Control Study: retrospective from Outcome to Exposure; fast, ideal for RARE DISEASES or long latency, calculates Odds Ratio (OR = ad/bc); prone to Recall & Selection Bias. |
| 28 | Compare the emergency management and fluid/electrolyte priorities of Diabetic Ketoacidosis (DKA) and Hyperosmolar Hyperglycemic State (HHS). | Start aggressive IV 0.9% Normal Saline FIRST before IV regular insulin (0.1 U/kg/hr). Check serum K⁺ before insulin: if K⁺ < 3.3 mEq/L, HOLD insulin and give KCl first; if K⁺ is 3.3–5.2 mEq/L, add 20–30 mEq KCl/L alongside insulin. In DKA, when glucose falls to 200 mg/dL, add 5% Dextrose while CONTINUING IV insulin until the Anion Gap closes. | High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors. | A) Start aggressive IV 0.9% Normal Saline FIRST before IV regular insulin (0.1 U/kg/hr). Check serum K⁺ before insulin: if K⁺ < 3.3 mEq/L, HOLD insulin and give KCl first; if K⁺ is 3.3–5.2 mEq/L, add 20–30 mEq KCl/L alongside insulin. In DKA, when glucose falls to 200 mg/dL, add 5% Dextrose while CONTINUING IV insulin until the Anion Gap closes. ✓; B) YELLOW (incineration): anatomical waste, blood-soiled dressings/plaster casts, expired medicines, microbiology cultures.; C) Thalidomide: Phocomelia; Isotretinoin: craniofacial, thymic & cardiac defects; Valproate/Carbamazepine: Neural tube defects; Phenytoin: Fetal Hydantoin syndrome (cleft palate, nail hypoplasia); Lithium:…; D) Minimal Change Disease (most common in children): normal LM, negative IF, podocyte foot process effacement on EM; selective albuminuria; steroid-responsive. |
| 29 | Outline the National Immunization Schedule (UIP) in India from birth to 16 years, including Fractional IPV (fIPV), Rotavirus, and PCV. | Birth: BCG (ID, left arm, NS diluent), OPV-0, HepB. At 6, 10, 14 wks: OPV-1/2/3, Pentavalent-1/2/3, Rotavirus-1/2/3, fIPV (6, 14 wks & 9m), PCV (6, 14 wks & 9m booster). At 9–12m: MR-1 (SC, right arm, sterile water), JE-1, Vit A (1 lakh IU). At 16–24m: DPT-B1, OPV-B, MR-2, JE-2, Vit A (2 lakh IU q6m). At 5–6 yrs: DPT-B2; 10 & 16 yrs: Td. | High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors. | A) Birth: BCG (ID, left arm, NS diluent), OPV-0, HepB. At 6, 10, 14 wks: OPV-1/2/3, Pentavalent-1/2/3, Rotavirus-1/2/3, fIPV (6, 14 wks & 9m), PCV (6, 14 wks & 9m booster). At 9–12m: MR-1 (SC, right arm, sterile water), JE-1, Vit A (1 lakh IU). At 16–24m: DPT-B1, OPV-B, MR-2, JE-2, Vit A (2 lakh IU q6m). At 5–6 yrs: DPT-B2; 10 & 16 yrs: Td. ✓; B) Series Testing (Test B done only if Test A is positive; positive only if BOTH A and B are positive): DECREASES net Sensitivity and NPV, but INCREASES net Specificity and PPV.; C) SGLT2 Inhibitors (Empagliflozin, Dapagliflozin): block proximal SGLT2 causing glucosuria, weight loss, and HFrEF/CKD benefit, but risk Euglycemic DKA and Fournier gangrene.; D) Beck's (Tamponade): hypotension, ↑ JVP, muffled heart sounds. |
| 30 | Match the classic Teratogenic Drugs with the specific congenital malformations they cause in the fetus. | Thalidomide: Phocomelia; Isotretinoin: craniofacial, thymic & cardiac defects; Valproate/Carbamazepine: Neural tube defects; Phenytoin: Fetal Hydantoin syndrome (cleft palate, nail hypoplasia); Lithium: Ebstein anomaly; Warfarin: Chondrodysplasia punctata; ACEi/ARBs: Renal dysgenesis; Methimazole: Aplasia cutis; DES: Vaginal clear cell cancer. | High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors. | A) Type I (Immediate): IgE cross-linking on mast cells (anaphylaxis, asthma).; B) Beck's (Tamponade): hypotension, ↑ JVP, muffled heart sounds.; C) Open Vial Policy APPLIES to liquid multi-dose vials (usable up to 28 days at +2°C to +8°C if VVM is active): OPV, DPT, Td, Hepatitis B, Pentavalent, liquid IPV, and PCV.; D) Thalidomide: Phocomelia; Isotretinoin: craniofacial, thymic & cardiac defects; Valproate/Carbamazepine: Neural tube defects; Phenytoin: Fetal Hydantoin syndrome (cleft palate, nail hypoplasia); Lithium: Ebstein anomaly; Warfarin: Chondrodysplasia punctata; ACEi/ARBs: Renal dysgenesis; Methimazole: Aplasia cutis; DES: Vaginal clear cell cancer. ✓ |
| 31 | Compare Iron Deficiency Anemia, Anemia of Chronic Disease, Beta-Thalassemia Trait, and Sideroblastic Anemia (Microcytic Hypochromic Anemias). | Iron Deficiency: ↓ Iron, ↓ Ferritin (most specific), ↑ TIBC, ↑ RDW. Anemia of Chronic Disease (↑ Hepcidin): ↓ Iron, ↑ Ferritin, ↓ TIBC. Beta-Thalassemia Trait: Normal Iron/Ferritin, Mentzer Index (MCV/RBC) < 13, HbA₂ > 3.5% on HPLC. Sideroblastic Anemia (INH/B6, Lead, Alcohol): ↑ Iron, ↑ Ferritin, ↓ TIBC, Prussian blue Ringed Sideroblasts. | High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors. | A) Beck's (Tamponade): hypotension, ↑ JVP, muffled heart sounds.; B) Sub-Centre (Ayushman Arogya Mandir): 5,000 in plains and 3,000 in hilly/tribal areas.; C) Iron Deficiency: ↓ Iron, ↓ Ferritin (most specific), ↑ TIBC, ↑ RDW. Anemia of Chronic Disease (↑ Hepcidin): ↓ Iron, ↑ Ferritin, ↓ TIBC. Beta-Thalassemia Trait: Normal Iron/Ferritin, Mentzer Index (MCV/RBC) < 13, HbA₂ > 3.5% on HPLC. Sideroblastic Anemia (INH/B6, Lead, Alcohol): ↑ Iron, ↑ Ferritin, ↓ TIBC, Prussian blue Ringed Sideroblasts. ✓; D) Paracetamol: N-acetylcysteine; Organophosphates: Atropine + Pralidoxime; Benzodiazepines: Flumazenil; Opioids: Naloxone; Beta-blockers: Glucagon; CCBs: IV Calcium + High-dose insulin; Methanol/Ethylene… |
| 32 | How do Sensitivity, Specificity, Positive Predictive Value (PPV), and Negative Predictive Value (NPV) change when disease prevalence increases? | Sensitivity [TP/(TP+FN), rules OUT disease when negative — SnNout] and Specificity [TN/(TN+FP), rules IN disease when positive — SpPin] are intrinsic test properties and DO NOT change with prevalence. As disease prevalence increases, Positive Predictive Value [TP/(TP+FP)] INCREASES, whereas Negative Predictive Value [TN/(TN+FN)] DECREASES. | High-yield exam verification (NEET PG, INI-CET & FMGE Clinical Medicine): distinguish the controlling statutory/doctrinal rule, timeframe, and exception from common test distractors. | A) Paracetamol: N-acetylcysteine; Organophosphates: Atropine + Pralidoxime; Benzodiazepines: Flumazenil; Opioids: Naloxone; Beta-blockers: Glucagon; CCBs: IV Calcium + High-dose insulin; Methanol/Ethylene…; B) Aschoff bodies & Anitschkow myocytes: Rheumatic heart disease; Reed-Sternberg (CD15+ CD30+) cells: Classic Hodgkin lymphoma; Birbeck granules (CD1a+, Langerin+): Langerhans histiocytosis; Call-Exner…; C) Sensitivity [TP/(TP+FN), rules OUT disease when negative — SnNout] and Specificity [TN/(TN+FP), rules IN disease when positive — SpPin] are intrinsic test properties and DO NOT change with prevalence. As disease prevalence increases, Positive Predictive Value [TP/(TP+FP)] INCREASES, whereas Negative Predictive Value [TN/(TN+FN)] DECREASES. ✓; D) Under Light's Criteria, a pleural effusion is EXUDATIVE if AT LEAST ONE is met: 1. |

---
Study this deck interactively with FSRS-6 spaced repetition, audio review, and multiple-choice mode at [Flashcards World](https://flashcards.world/flashcards/sets/ec6156c2-af77-4a7a-a0c5-8857f5b019ec/).
